1404-26-8

Basic information

• Product Name: Polymyxin B
• Synonyms: polymyxin B 2.5sulfate entahydrate;Polymyxin B (base and/or unspecified salts);Polymyxin E see Colistin
• CAS NO: 1404-26-8
• Molecular Formula: C55H96N16O13
• Molecular Weight: 1015.41
• EINECS: 215-768-4
• Mol File: 1404-26-8.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 1651 °C at 760 mmHg
• Flash Point: 952.3 °C
• Appearance: /
• Density: g/cm³
• CAS DataBase Reference: Polymyxin B(CAS DataBase Reference)
• NIST Chemistry Reference: Polymyxin B(1404-26-8)
• EPA Substance Registry System: Polymyxin B(1404-26-8)

Safety Data

• Hazardous Substances Data: 1404-26-8(Hazardous Substances Data)

Usage

Description

Polymyxin B is a type of polymyxin antibiotic that possesses potent antibacterial properties. It is characterized by a 6-methylheptanoyl group at the amino terminus, which contributes to its effectiveness against certain bacteria. Polymyxin B is derived from the bacterium Bacillus polymyxa and is known for its ability to disrupt bacterial cell membranes, leading to cell death.

Uses

Used in Pharmaceutical Industry:
Polymyxin B is used as an antibiotic for the treatment of severe bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii. It is particularly effective against multidrug-resistant bacteria and is often used as a last resort when other antibiotics have failed.
Used in Antimicrobial Aerosporin:
Polymyxin B is also used as an antimicrobial agent in aerosporin, a substance produced by certain bacteria that can inhibit the growth of other bacteria. This application helps to maintain a balance of microbial populations and prevent the overgrowth of harmful bacteria.
Brand names:
Some of the brand names under which Polymyxin B is marketed include Poly-Rx (X Gen) and a product by GlaxoSmithKline. These formulations make the antibiotic more accessible to healthcare professionals and patients in need of effective treatment options for bacterial infections.

Contact allergens

Active against Gram-negative bacteria, Polymyxin B is a mixture of Polymyxin B1 and B2. Sensitization occurs by topical, ophthalmic, and otic preparations. Cosensitization is frequent with other topical antibiotics like neomycin or bacitracin.

Related news

Brief communicationEarly use of Polymyxin B (cas 1404-26-8) reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection09/10/2019

Polymyxin B is one of the last resort option for carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infection in China. Therefore, the timing of administration of polymyxin is frequently delayed. We collected 40 cases of CRKP bloodstream infections (BSIs) treated with combinations bas...detailed

Antimicrobial Susceptibility StudyStaggering the administration of Polymyxin B (cas 1404-26-8) and meropenem in time-kill against carbapenem-resistant Enterobacteriaceae exhibiting a wide range of meropenem MICs09/09/2019

Little is known regarding the appropriate timing and sequencing of a carbapenem and polymyxin in combination against carbapenem-resistant Enterobacteriaceae. Meropenem and polymyxin B were administered simultaneously or 1 agent 2 h prior to the other, in vitro. The carbapenem should be administe...detailed

Combination therapy with Polymyxin B (cas 1404-26-8) for carbapenemase-producing Klebsiella pneumoniae bloodstream infection09/07/2019

ABSTRACTKlebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) bloodstream infections (BSIs) are related to high mortality rates, and combination therapy has been associated with lower mortality in patients treated mostly with colistin. There is a paucity of studies addressing poly...detailed

An alternative strategy for combination therapy: Interactions between Polymyxin B (cas 1404-26-8) and non-antibiotics09/06/2019

Antimicrobial resistance is increasing and few new antibiotics are in the development pipeline. Alternative strategies to treat infectious diseases, such as combination therapy, are urgently needed. Polymyxin B is a neglected and disused antibiotic with moderate antibacterial activity. In this s...detailed

Original articlePolymyxin B (cas 1404-26-8) Etest® compared with gold-standard broth microdilution in carbapenem-resistant Enterobacteriaceae exhibiting a wide range of Polymyxin B (cas 1404-26-8) MICs09/05/2019

ObjectivesPolymyxins have been revitalized to combat carbapenem-resistant Enterobacteriaceae (CRE). However, evaluating the activity of these agents by traditional broth dilution methods is not practical for busy clinical laboratories. We compared polymyxin B activity using two quantitative susc...detailed

Comparison of the composition and in vitro activity of Polymyxin B (cas 1404-26-8) products09/04/2019

ABSTRACTA number of companies manufacture polymyxin B using United States Pharmacopeia (USP) metrics, rather than chemical composition, to report biological activity. Given that polymyxin B contains several different components, it is unknown whether pharmacokinetic and pharmacodynamic variabili...detailed

Co-delivery of buparvaquone and Polymyxin B (cas 1404-26-8) in nanostructured lipid carrier for leishmaniasis treatment09/03/2019

ObjectivesThe objective of this study was to describe the preparation and in vitro evaluation of the surface modified nanostructured lipid carrier (NLC) using chitosan and dextran in the co-delivery of buparvaquone (BPQ) and polymyxin B (PB) against leishmaniasis.detailed

Polymyxin B (cas 1404-26-8) and polymyxin E induce anaphylactoid response through mediation of Mas-related G protein–coupled receptor X209/01/2019

Polymyxin B (PMB) and polymyxin E (PME) are cyclic, peptide antibiotics which derived from various species of Paenibacillus (Bacillus) polymyxa. They are decapeptide antibiotics with an antimicrobial spectrum that includes Gram-negative bacteria, and reused as therapeutic agents due to the emerg...detailed